VaxSyna

VaxSyna is a private, early-stage biotechnology company developing low-cost vaccines and antibody-based therapeutics for infectious diseases and cancer. The company’s core technology is a patented antibody fusion platform in which a human IgG is linked to target antigens and an epitope tag, enabling self-assembling higher-order immune complexes that can drive strong immune responses with minimal doses and potentially without adjuvant. VaxSyna emphasizes plant-based production to reduce manufacturing cost and improve scalability, with a particular focus on vaccines suited for global health settings and low- and middle-income countries. Its disclosed pipeline includes a broad-spectrum HPV vaccine program and preclinical work in herpes simplex virus and Zika virus vaccines. The company appears to remain privately held and grant-backed, with a small team and operations centered in New Hampshire/Boston.